Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Short-term Investments (2021 - 2025)

AVITA Medical's Short-term Investments history spans 5 years, with the latest figure at $7.9 million for Q4 2025.

  • For Q4 2025, Short-term Investments fell 63.63% year-over-year to $7.9 million; the TTM value through Dec 2025 reached $7.9 million, down 63.63%, while the annual FY2025 figure was $7.9 million, 63.63% down from the prior year.
  • Short-term Investments reached $7.9 million in Q4 2025 per RCEL's latest filing, up from $7.9 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $66.9 million in Q4 2023 to a low of $3.5 million in Q2 2025.
  • Average Short-term Investments over 5 years is $33.7 million, with a median of $29.7 million recorded in 2021.
  • Peak YoY movement for Short-term Investments: soared 178.13% in 2024, then crashed 90.51% in 2025.
  • A 5-year view of Short-term Investments shows it stood at $29.6 million in 2021, then surged by 106.34% to $61.2 million in 2022, then rose by 9.42% to $66.9 million in 2023, then plummeted by 67.38% to $21.8 million in 2024, then crashed by 63.63% to $7.9 million in 2025.
  • Per Business Quant, the three most recent readings for RCEL's Short-term Investments are $7.9 million (Q4 2025), $7.9 million (Q3 2025), and $3.5 million (Q2 2025).